Predicting Which Lung Nodules Will Progress to Cancer
Researchers developed a risk prediction model that could categorize individuals with lung nodules as having high or low risk for lung cancer.
Progress Against Cancer
Researchers developed a risk prediction model that could categorize individuals with lung nodules as having high or low risk for lung cancer.
Once the leading cause of cancer-related mortality among women, cervical cancer now accounts for less than 1 percent of cancer-related deaths among women in the United States. This dramatic decrease is largely due to the implementation of screening, which can detect precancerous lesions and early-stage cancer, and vaccination, which can prevent the cancer from developing at all.
Cervical cancer patients may benefit from addressing any stress disorders they might have, as it could potentially improve their cancer prognosis.
A study found that exposure to World Trade Center dust may alter inflammatory pathways, leading to the progression of prostate cancer.
Understanding brain metastasis risk could influence screening, surveillance practices, a study of breast cancer, lung cancer, and melanoma patients found.
A large study of postmenopausal women showed strong benefit from smoking cessation in lowering the risk of bladder cancer. Bladder cancer is the most common malignancy of the urinary system. Some 80,470 new diagnoses...
Following dietary recommendations may reduce the risk of several cancers, a study in the AACR journal Cancer Research reports. Learn more.
Study: Initial treatment with an immune checkpoint inhibitor was associated with longer survival of patients with melanoma that had spread to the brain.
A recent study found that less than 13 percent of baby boomers were screened for the virus despite the recent approval of several effective treatments. Almost half of liver cancer cases in the United...
A study found declines in lung cancer death rates among women in the United States have lagged in two geographic hot spots.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More